Start › Glejak › Nowy Jork › New York City
Badania kliniczne dla Glejak w mieście New York City, NY
25 badań dla Glejak szuka uczestników w ośrodkach w mieście New York City i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RekrutacjaFaza 1/2
- Research Site, New York
- Research Site, New York
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
RekrutacjaFaza 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RekrutacjaFaza 2
- Columbia University Irving Medical Center, New York
A Study of Mirdametinib in People With Central Nervous System Tumors
RekrutacjaFaza 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Glioma Developmental and HyperActive Ras Tumor (DHART) Board
RekrutacjaBadanie obserwacyjne
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RekrutacjaFaza 3
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- i 1 więcej
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
RekrutacjaFaza 1
- New York University, New York
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RekrutacjaFaza 4
- New York Presbyterian Hospital-Columbia University Medical Center, New York
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
RekrutacjaFaza 1
- NYU Langone Health, New York
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RekrutacjaFaza 2
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
RekrutacjaFaza 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Rekrutacja
- NYU Langone Health, New York
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
RekrutacjaFaza 1/2
- Memorial Sloan Kettering Cancer Center, New York
Chronic CED of TPT for Recurrent Malignant Glioma
RekrutacjaFaza 1
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York
A Study of 177Lu-PSMA-617 in People With Gliomas
RekrutacjaFaza 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
RekrutacjaFaza 3
- Lenox Hill Brain Tumor Center, New York
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Rekrutacja
- Lenox Hill Brain Tumor Center, New York
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Rekrutacja
- Lenox Hill Brain Tumor Center, New York
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RekrutacjaFaza 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Columbia University Medical Center, New York
- Memorial Slone Kettering Cancer Center, New York
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
RekrutacjaFaza 1
- Memorial Sloan Kettering, New York
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RekrutacjaFaza 1/2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RekrutacjaFaza 2
- Lenox Hill Brain Tumor Center, New York
FUS Etoposide for DMG
RekrutacjaFaza 1
- Columbia University Irving Medical Center, New York
Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
RekrutacjaWczesna faza 1
- NYU Langone Health, New York
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
Rekrutacja
- Memorial Sloan Kettering Cancer Center, New York
Badania dla Glejak w innych miastach
- Houston, TX23 badań
- Boston, MA20 badań
- Washington, DC19 badań
- Philadelphia, PA16 badań
- Columbus, OH15 badań
- Miami, FL15 badań
- San Francisco, CA14 badań
- Chicago, IL13 badań
- Durham, NC12 badań
- Seattle, WA11 badań
- St. Louis, MO10 badań
- Aurora, CO10 badań
Inne badania w mieście New York City
- Rak piersi136 badań
- Niedrobnokomórkowy rak płuca121 badań
- Nowotwory (wszystkie typy)109 badań
- Rak prostaty103 badań
- Nowotwór przerzutowy93 badań
- Rak jelita grubego i odbytnicy78 badań
- Rak jajnika69 badań
- Rak płuc60 badań
- Szpiczak mnogi60 badań
- Rak trzustki60 badań
- Rak endometrium52 badań
- Ostra białaczka szpikowa51 badań
Źródło: ClinicalTrials.gov, dane pobrane 6 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.